Variable | Hazard ratio | 95% CI | p value | |
---|---|---|---|---|
 | Lower | Upper | ||
Age at biopsy, yr | 1.040 | 0.977 | 1.108 | 0.220 |
Sex, female | 0.432 | 0.122 | 1.526 | 0.193 |
Pack-year of smoking | 0.993 | 0.978 | 1.008 | 0.367 |
Symptom onset, mo | 1.001 | 0.994 | 1.009 | 0.737 |
Extent score on HRCT before AE | 1.127 | 0.970 | 1.311 | 0.119 |
FVC before AE, % pred | 0.989 | 0.956 | 1.023 | 0.514 |
FEV1/FVC, % | 0.953 | 0.877 | 1.035 | 0.249 |
DLCO before AE, % pred | 0.987 | 0.958 | 1.018 | 0.416 |
Resting PaO2, mmHg | 0.999 | 0.961 | 1.039 | 0.961 |
Distance in six-minute walk test | 0.998 | 0.992 | 1.005 | 0.609 |
Minimum SpO2 in six-minute walk test | 0.960 | 0.884 | 1.043 | 0.338 |
Serum LDH, IU/L | 1.003 | 0.997 | 1.008 | 0.305 |
Serum KL-6, U/mL | 1.000 | 1.000 | 1.000 | 0.447 |
Serum SP-D, ng/mL | 0.999 | 0.997 | 1.001 | 0.256 |
The GAP staging system before AE | 1.089 | 0.639 | 1.854 | 0.754 |
Preceding treatments for IPF, + | 0.913 | 0.399 | 2.088 | 0.829 |
Preceding oxygen therapy, + | 1.662 | 0.678 | 4.074 | 0.267 |
P/F ratio at AE | 0.999 | 0.994 | 1.003 | 0.565 |
Extent score on HRCT at AE | 1.077 | 0.954 | 1.215 | 0.231 |
Period from admission to commencement of treatments for AE, day | 1.104 | 0.985 | 1.237 | 0.090 |
Administration of Immunosuppressant for AE, + | 1.403 | 0.548 | 3.593 | 0.481 |
Administration of Sivelestat sodium hydrate for AE, + | 0.787 | 0.290 | 2.131 | 0.637 |
PMX-DHP, + | 0.399 | 0.161 | 0.988 | 0.047 |
ΔWBC 2 days after commencement of treatments for AE, /μL | 1.000 | 1.000 | 1.000 | 0.423 |
ΔNeutrophil 2 days after commencement of treatments for AE, /μL | 1.000 | 1.000 | 1.000 | 0.607 |
ΔP/F ratio 2 days after commencement of treatments for AE | 0.990 | 0.983 | 0.997 | 0.008 |
ΔLDH 2 days after commencement of treatments for AE, IU/L | 1.006 | 1.002 | 1.011 | 0.009 |
ΔAngiopoietin-2 2 days after commencement of treatments for AE, pg/mL | 1.000 | 1.000 | 1.001 | 0.307 |